Warning: Undefined variable $hero_has_title in /srv/home/gcurenl/domains/gcure.nl/htdocs/www/custom/themes/cardiologie/includes/heroes/hero-page.php on line 50

STOP-HF

Stem cell models to unravel the susceptibility and resilience to develop heart failure

The overarching objective of STOP-HF is to generate human induced pluripotent stem cells (hiPSC) derived cardiomyocytes from two specific forms of heart failure (HF) with a clear trigger to unravel common pathophysiological mechanisms involved in the early development of HF.

The project is focused on two specific forms of HF, both with a clear trigger: pregnancy and anthracyclines. Better understanding of early molecular pathways leading to HF and knowledge about inter-individual susceptibility is needed. For detection of early changes on a molecular level cardiac tissue is needed. Generation of patient specific cardiac cells from skin fibroblasts (hiPSC technology) is a novel and innovative approach.

 

Specific objectives
1. Fabrication and maturation of 3D cardiac tissue from hiPSC derived cardiomyocytes.
2. Generate and characterize hiPSC derived cardiomyocytes and endothelial cells from females with pregnancy induced HF and unravel differences on transcriptome level.
3. Generate and characterize hiPSC derived cardiomyocytes from patients with high susceptibility and resilience to develop anthracycline-induced HF and compare them on transcriptome level.
4. Integrate the results for coding and non-coding RNAs from objective 1+2 and identify overlapping pathways.
5. Validate discoveries on transcriptome level in vitro, in vivo and apply for the development of HF in the general population.

 

Workpackages
WP1: Optimize fabrication and maturation of 3D cardiac tissue from hiPSC derived cardiomyocytes
WP2A: Validate the model and compare hiPSC derived cardiomyocytes and endothelial cells from PPCM and healthy sisters on transcriptome level;
WP2B: Validate the model and compare hiPSC derived cardiomyocytes from both patients with high susceptibility and resilience to develop HF after anthracyclins on transcriptome level;
WP3: Integration of transcriptome data from WP 2A+2B;
WP4: Validation of novel pathways in vitro, in vivo and new onset HF in the general population.

People involved

Principal investigator

Peter van der Meer

Cardiologist

International collaborations

  • Adam W. Feinberg (Carnegie Mellon University)
  • Denise Kleiner-Hilfiker (Hannover Medical School)
  • Karen Sliwa (University of Cape Town)